Show simple item record

dc.contributor.authorDoğu, Figen
dc.date.accessioned2020-11-20T08:08:56Z
dc.date.available2020-11-20T08:08:56Z
dc.date.issued2019
dc.identifier.urihttps://doi.org/10.1016/j.jaip.2018.10.035tr_TR
dc.identifier.urihttp://hdl.handle.net/20.500.12575/72488
dc.description.abstractBackground: Biallelic variations in the dedicator of cytokinesis 8 (DOCK8) gene cause a combined immunodeficiency with eczema, recurrent bacterial and viral infections, and malignancy. Natural disease outcome is dismal, but allogeneic hematopoietic stem cell transplantation (HSCT) can cure the disease. Objective: To determine outcome of HSCT for DOCK8 deficiency and define possible outcome variables. Methods: We performed a retrospective study of the results of HSCT in a large international cohort of DOCK8-deficient patients. Results: We identified 81 patients from 22 centers transplanted at a median age of 9.7 years (range, 0.7-27.2 years) between 1995 and 2015. After median follow-up of 26 months (range, 3-135 months), 68 (84%) patients are alive. Severe acute (III-IV) or chronic graft versus host disease occurred in 11% and 10%, respectively. Causes of death were infections (n = 5), graft versus host disease (5), multiorgan failure (2), and preexistent lymphoma (1). Survival after matched related (n = 40) or unrelated (35) HSCT was 89% and 81%, respectively. Reduced-toxicity conditioning based on either treosulfan or reduced-dose busulfan resulted in superior survival compared with fully myeloablative busulfan-based regimens (97% vs 78%; P = .049). Ninety-six percent of patients younger than 8 years at HSCT survived, compared with 78% of those 8 years and older (P = .06). Of the 73 patients with chimerism data available, 65 (89%) had more than 90% donor T-cell chimerism at last follow-up. Not all disease manifestations responded equally well to HSCT: eczema, infections, and mollusca resolved quicker than food allergies or failure to thrive. Conclusions: HSCT is curative in most DOCK8-deficient patients, confirming this approach as the treatment of choice. HSCT using a reduced-toxicity regimen may offer the best chance for survival.tr_TR
dc.language.isoentr_TR
dc.relation.isversionof10.1016/j.jaip.2018.10.035tr_TR
dc.subjectCombined immunodeficiencytr_TR
dc.subjectDOCK8 deficiencytr_TR
dc.subjectHSCTtr_TR
dc.titleHematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiencytr_TR
dc.typeArticletr_TR
dc.relation.journalJ Allergy Clin Immunol Pract .tr_TR
dc.contributor.departmentTıp Fakültesitr_TR
dc.identifier.volume7tr_TR
dc.identifier.issue3tr_TR
dc.identifier.startpage1tr_TR
dc.identifier.endpage18tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıtr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record